1
|
Saland E, Boutzen H, Castellano R, Pouyet L, Griessinger E, Larrue C, de Toni F, Scotland S, David M, Danet-Desnoyers G, Vergez F, Barreira Y, Collette Y, Récher C, Sarry JE. A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia. Blood Cancer J 2015; 5:e297. [PMID: 25794133 PMCID: PMC4382660 DOI: 10.1038/bcj.2015.19] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2015] [Accepted: 02/02/2015] [Indexed: 11/25/2022] Open
Abstract
Relevant preclinical mouse models are crucial to screen new therapeutic agents for acute myeloid leukemia (AML). Current in vivo models based on the use of patient samples are not easy to establish and manipulate in the laboratory. Our objective was to develop robust xenograft models of human AML using well-characterized cell lines as a more accessible and faster alternative to those incorporating the use of patient-derived AML cells. Five widely used AML cell lines representing various AML subtypes were transplanted and expanded into highly immunodeficient non-obese diabetic/LtSz-severe combined immunodeficiency IL2Rγcnull mice (for example, cell line-derived xenografts). We show here that bone marrow sublethal conditioning with busulfan or irradiation has equal efficiency for the xenotransplantation of AML cell lines. Although higher number of injected AML cells did not change tumor engraftment in bone marrow and spleen, it significantly reduced the overall survival in mice for all tested AML cell lines. On the basis of AML cell characteristics, these models also exhibited a broad range of overall mouse survival, engraftment, tissue infiltration and aggressiveness. Thus, we have established a robust, rapid and straightforward in vivo model based on engraftment behavior of AML cell lines, all vital prerequisites for testing new therapeutic agents in preclinical studies.
Collapse
Affiliation(s)
- E Saland
- 1] Cancer Research Center of Toulouse, INSERM, U1037, Toulouse, France [2] University of Toulouse, Toulouse, France
| | - H Boutzen
- 1] Cancer Research Center of Toulouse, INSERM, U1037, Toulouse, France [2] University of Toulouse, Toulouse, France
| | - R Castellano
- 1] Cancer Research Center of Marseille, INSERM, U1068, Marseille, France [2] Institut Paoli-Calmettes, Marseille, France [3] Aix-Marseille Université, Marseille, France [4] CNRS, UMR7258, Marseille, France
| | - L Pouyet
- 1] Cancer Research Center of Marseille, INSERM, U1068, Marseille, France [2] Institut Paoli-Calmettes, Marseille, France [3] Aix-Marseille Université, Marseille, France [4] CNRS, UMR7258, Marseille, France
| | - E Griessinger
- 1] Centre Méditerranéen de Médecine Moléculaire, INSERM, U1065, Nice, France [2] Université de Nice Sophia Antipolis, Nice, France
| | - C Larrue
- 1] Cancer Research Center of Toulouse, INSERM, U1037, Toulouse, France [2] University of Toulouse, Toulouse, France
| | - F de Toni
- 1] Cancer Research Center of Toulouse, INSERM, U1037, Toulouse, France [2] University of Toulouse, Toulouse, France
| | - S Scotland
- 1] Cancer Research Center of Toulouse, INSERM, U1037, Toulouse, France [2] University of Toulouse, Toulouse, France
| | - M David
- 1] Cancer Research Center of Toulouse, INSERM, U1037, Toulouse, France [2] University of Toulouse, Toulouse, France
| | - G Danet-Desnoyers
- Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
| | - F Vergez
- 1] Cancer Research Center of Toulouse, INSERM, U1037, Toulouse, France [2] University of Toulouse, Toulouse, France
| | - Y Barreira
- Service d'Expérimentation Animale, UMS006, 31059, Toulouse cedex, France
| | - Y Collette
- 1] Cancer Research Center of Marseille, INSERM, U1068, Marseille, France [2] Institut Paoli-Calmettes, Marseille, France [3] Aix-Marseille Université, Marseille, France [4] CNRS, UMR7258, Marseille, France
| | - C Récher
- 1] Cancer Research Center of Toulouse, INSERM, U1037, Toulouse, France [2] University of Toulouse, Toulouse, France [3] Département d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse cedex, France
| | - J-E Sarry
- 1] Cancer Research Center of Toulouse, INSERM, U1037, Toulouse, France [2] University of Toulouse, Toulouse, France
| |
Collapse
|
6
|
Pramanik K, Trüpschuch S, Greiner A, Ruthardt M, Henschler R, Müller AM. The aorta-gonad-mesonephros-derived stroma cell line DAS104-4 induces differentiation of leukemic cells. Leuk Res 2007; 32:781-9. [PMID: 17980910 DOI: 10.1016/j.leukres.2007.09.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2007] [Revised: 09/11/2007] [Accepted: 09/16/2007] [Indexed: 02/02/2023]
Abstract
While critical steps in the regulation of leukemia cell development have been intensively studied in recent years, less is known about the interactions of leukemic cells with their stroma. Previously, we have shown that human acute myeloid leukemia (AML) cells differentiate upon injection into murine blastocysts. We here describe that human AML Kasumi-1 cells, cocultured with murine aorta-gonad-mesonephros (AGM) region-derived DAS104-4 stromal cells, decrease proliferation and colony formation efficiency; and up-regulate myelo-monocytic cell surface markers. Gene expression analysis showed decreased transcription of the AML1-ETO fusion gene and increased transcription of p16 (INK4A), p21 (WAF1) and C/EBPalpha genes. Coculture can induce myeloid differentiation also in patient-derived AML cells. Our findings strengthen the notion that the embryonic milieu can regulate the proliferation and differentiation of leukemic cells.
Collapse
Affiliation(s)
- Kallal Pramanik
- Institut für Medizinische Strahlenkunde und Zellforschung (MSZ), Universität Würzburg, Versbacherstr. 5, D-97078 Würzburg, Germany
| | | | | | | | | | | |
Collapse
|
7
|
Lee EM, Bachmann PS, Lock RB. Xenograft models for the preclinical evaluation of new therapies in acute leukemia. Leuk Lymphoma 2007; 48:659-68. [PMID: 17454623 DOI: 10.1080/10428190601113584] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Major advances in understanding the pathophysiology of acute leukemia have resulted in a dramatic increase in the availability of novel compounds for clinical trials. However, since the number of new drugs far exceeds the number of clinical trials that can be conducted because of the availability of eligible patients, there is an urgent need to utilize reliable preclinical models for the prioritization of the most promising potential therapies for those clinical trials. The most widely used preclinical models for the acute leukemias are human tumor xenografts established in immune-deficient mice, and genetically engineered mouse strains. This review summarizes the recent developments and considerations in the use of xenograft models of acute lymphoblastic leukemia, acute myeloid leukemia, and acute promyelocytic leukemia for the preclinical testing of new therapies.
Collapse
Affiliation(s)
- Erwin M Lee
- Children's Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, Australia
| | | | | |
Collapse
|
8
|
Hayashi M, Kondoh K, Nakata Y, Kinoshita A, Mori T, Takahashi T, Sakamoto MI, Yamada T. Establishment of a novel childhood acute myeloid leukaemia cell line, KOPM-88, containing partial tandem duplication of the MLL gene and an in vivo model for childhood acute myeloid leukaemia using NOD/SCID mice. Br J Haematol 2007; 137:221-32. [PMID: 17408461 DOI: 10.1111/j.1365-2141.2007.06553.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
MLL gene rearrangement is common in both adult and childhood acute myeloid leukaemia (AML), and its role in oncogenesis has been investigated. While over 50 translocated-partner genes have been identified so far, few studies have detailed the molecular mechanism of partial tandem duplication (PTD) of the MLL gene. The prognostic impact and contribution to leukaemogenesis of MLL-PTD, especially in childhood cases, remain unknown. We have established a novel cell line containing MLL-PTD derived from an 11-year-old patient with AML and designated as KOPM-88. KOPM-88 cells exhibited certain characteristics associated with the myeloid lineage including abundant primary granules in the cytoplasm and the expression of myeloperoxidase. The cell growth of KOPM-88 was cytokine independent but was accelerated by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. MLL-PTD of exon 2 to exon 6 and exon 2 to exon 8 was revealed using Southern blotting, fluorescence in situ hybridisation, and reverse transcription polymerase chain reaction/DNA sequencing. Furthermore, non-obese diabetic/severe combined immunodeficient mice inoculated with KOPM-88 cells exhibited leukaemic infiltrations in the bone marrow and hemiparalysis because of compression myelopathy. This is the first report of an in vivo animal model exhibiting the systemic involvement of childhood AML containing MLL-PTD. KOPM-88 cells and our murine model may be useful for investigating the pathogenesis of childhood AML associated with MLL gene rearrangement.
Collapse
MESH Headings
- Animals
- Antigens, Surface/immunology
- Cell Division/immunology
- Cell Line, Tumor
- Cell Transplantation/methods
- Child
- Cytokines/immunology
- Disease Models, Animal
- Fatal Outcome
- Flow Cytometry/methods
- Gene Duplication
- Gene Rearrangement/genetics
- Histone-Lysine N-Methyltransferase
- Humans
- In Situ Hybridization, Fluorescence/methods
- Leukemia, Myeloid, Acute/genetics
- Leukemia, Myeloid, Acute/immunology
- Leukemia, Myeloid, Acute/pathology
- Male
- Mice
- Mice, Inbred NOD
- Mice, SCID
- Myeloid-Lymphoid Leukemia Protein/genetics
- Polymerase Chain Reaction/methods
- Tandem Repeat Sequences/genetics
Collapse
Affiliation(s)
- Mutsumi Hayashi
- Department of Pediatrics, and Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Riccioni R, Diverio D, Mariani G, Buffolino S, Riti V, Saulle E, Petrucci E, Cedrone M, Lo-Coco F, Foà R, Peschle C, Testa U. Expression of Tie-2 and Other Receptors for Endothelial Growth Factors in Acute Myeloid Leukemias Is Associated with Monocytic Features of Leukemic Blasts. Stem Cells 2007; 25:1862-71. [PMID: 17446561 DOI: 10.1634/stemcells.2006-0700] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
We investigated the expression of Tie-2 in primary blasts from 111 patients with acute myeloid leukemia (AML) to evaluate a possible linkage between the expression of this receptor and the immunophenotypic and biologic properties of leukemic blasts. Tie-2 was expressed at moderate and high levels in 39 and 23 of 111 AMLs, respectively. The analysis of the immunophenotype clearly showed that Tie-2 expression in AML was associated with monocytic features. Interestingly, Tie-2 expression on AML blasts was associated with concomitant expression of other receptors for endothelial growth factors, such as vascular endothelial growth factor receptor 1 (VEGF-R1), -R2, and -R3. Tie-2(+) AMLs were characterized by high blast cell counts at diagnosis, a high frequency of Flt3 mutations, and increased Flt3 expression. The survival of Tie-2(+) AMLs is sustained through an autocrine pattern involving Angiopoietin-1 and Tie-2, as suggested by experiments showing induction of apoptosis in Tie-2(+) AMLs by agents preventing the binding of angiopoietins to Tie-2. Finally, the in vitro growth of Tie-2(+) AMLs in endothelial culture medium supplemented with VEGF and angiopoietins resulted in their partial endothelial differentiation. These observations suggest that Tie-2(+) AMLs pertain to a mixed monocytic/endothelial lineage, derived from the malignant transformation of the normal counterpart represented by monocytic cells expressing endothelial markers. The autocrine angiopoietin/Tie-2 axis may represent a promising therapeutic target to improve the outcome of patients with monocytic AML. Disclosure of potential conflicts of interest is found at the end of this article.
Collapse
Affiliation(s)
- Roberta Riccioni
- Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Liu J, Li Y, Tang LJ, Zhang GP, Hu WX. Treatment of lycorine on SCID mice model with human APL cells. Biomed Pharmacother 2007; 61:229-34. [PMID: 17336028 PMCID: PMC7126558 DOI: 10.1016/j.biopha.2007.01.003] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2006] [Revised: 01/10/2007] [Accepted: 01/12/2007] [Indexed: 12/31/2022] Open
Abstract
In our previous study, lycorine, a natural alkaloid extracted from Amaryllidaceae, exhibited anti-leukemia effects in vitro. To determine whether lycorine has an anti-tumor effect in vivo, a series of experiments were carried out in this study. HL-60 cells (5 × 106) were inoculated i.v. into severe combined immuno-deficiency (SCID) mice after these mice had been irradiated (total body receiving 200 cGy χ irradiation). Treatment was given once a day from day 2 to 6, and from day 14 to 18. Lycorine (5 or 10 mg/kg/day i.p.) was found to decrease the percentages of immature granular leukocytes and of monocytes among the peripheral blood cells, and the mean survival time of both lycorine-treated groups was longer than that of the control group. Compared with the asynchronous and cytosine arabinoside- (Ara-C) treated (20 mg/kg/day i.p.) group, treatment with lycorine was more effective. Lycorine was also found to alleviate the infiltration of tumor cells into the liver, bone, and marrow. When SCID mice inoculated with HL-60 cells were then treated with lycorine, no severe adverse effects were observed. This study revealed that lycorine, when tested in the human leukemia xenograft models, appears to exhibit anti-tumor activity in vivo and is a useful therapy against acute promyelocytic leukemia.
Collapse
MESH Headings
- Amaryllidaceae Alkaloids/therapeutic use
- Animals
- Antineoplastic Agents, Phytogenic/therapeutic use
- Body Weight/drug effects
- Dose-Response Relationship, Drug
- Female
- HL-60 Cells
- Humans
- Leukemia, Promyelocytic, Acute/drug therapy
- Leukemia, Promyelocytic, Acute/mortality
- Leukemia, Promyelocytic, Acute/pathology
- Leukemic Infiltration
- Mice
- Mice, Inbred BALB C
- Mice, SCID
- Neoplasm Transplantation
- Phenanthridines/therapeutic use
- Survival Rate
- Transplantation, Heterologous
Collapse
Affiliation(s)
- J Liu
- Molecular Biology Research Center, School of Biological Science and Technology, Central South University, 110 Xiangya Road, Changsha, Hunan 410078, PR China
| | | | | | | | | |
Collapse
|